MisterBlues schreef op 26 oktober 2020 17:38:
[...]
Ook al zat deze schrijver aanvankelijk op het verkeerde spoor, zijn stuk maakt duidelijk hoe gecompliceerd de relatie NeuroRx / Relief is als het gaat om in aanmerking te komen voor OWS.
Including RLF-100 in Operation Warp Speed was always the logical outcome. I have mentioned it several times in my speculative posts that we should get OWS Funding. I have mentioned (just a day or two ago) that there is no way that NeuroRX could put in an offer (to treat 1m patients) to Bachem without a big downpayment (that some pharmacies similar to Bachem require a 50% downpayment on such orders). Bachem would never hire dozens of people and spend millions on expansion without getting paid upfront, when a huge order comes in from a tiny biotech startup with no cash and no revenues steam. I said it would have to be funded either by OWS or GEM, while it was always unlikely that the latter would take on such a risk. So OWS it is, and was the only logical conclusion. This means that we have been on the OWS radar for quite some time, as the order to Bachem was made a month ago and has been in the works for several months.
NeuroRX is getting the potential funding from OWS, not Relief. But it doesn't matter at all. Because Relief is getting 50% of the profits from US anyway, and as a Swiss company had 0% chance of getting OWS funding. NeuroRX does all the heavy lifting and we just count the dough as it rolls in. It is a fantastic setup for RLF Shareholders. That is why I think we got a steal of a deal with the 50% profit sharing in the US (was expecting 20% royalties on sales vs. 50% of gross profit we got). I always disagreed with those who thought we gave up to much. Without NeuroRX, Aviptadil never ever sees the light of day. The only reason we got so much (50%) is because we paid a few million dollars for the clinical trials and took the financial risk. Brilliant move by GEM and RAM! Had NeuroRX funded the trials, we would have been left with a much smaller profit sharing arrangement. This was the best possible outcome for RLF Shareholders.
Ram wasn't kidding that we will make sure to extract maximum value for RLF Shareholders from the Relief Therapeutics franchise. He is a Wall St. Analyst and Managing Director in a Wall St. Research Shop. He knows how to value companies, specializes in pharmaceutical drug pricing, and will not sell us short. We are in good hands all around.